Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Stability of Blood Clotting Products Stored in Emergency Ambulances Under Real-World Conditions (STABLE-EMS)

15 de junio de 2026 actualizado por: Medical University of Graz

Stability of Human Fibrinogen (Fibryga) and Lyophilized Human Plasma (Octaplas LG AB) Under Real-World Prehospital Emergency Medical Service Storage Conditions: A Prospective Observational Study

Emergency medical service (EMS) vehicles are exposed to a wide range of environmental conditions, including high temperatures during summer months. These conditions may affect the stability and quality of medications and blood products carried for emergency treatment.

This observational study aims to evaluate the stability of human fibrinogen concentrates and human plasma proteins (Octaplas) when stored under routine operating conditions in a ground-based EMS ambulance in Graz, Austria. Drug samples will be analyzed monthly over a four-month period and compared with reference samples stored under recommended conditions. In addition, temperature inside the storage containers and the vehicle will be continuously monitored.

The study will assess whether prolonged exposure to real-world prehospital storage conditions affects product stability and whether any changes are associated with environmental factors. The findings may help determine whether current storage practices in EMS vehicles are adequate for maintaining the quality of these blood coagulation products.

Descripción general del estudio

Estado

Aún no reclutando

Descripción detallada

Emergency medical service (EMS) medications and blood products are routinely exposed to varying environmental conditions during storage and transport. Seasonal temperature fluctuations, prolonged vehicle operation, and environmental influences may result in deviations from manufacturer-recommended storage conditions. While several studies have demonstrated the stability of commonly used emergency medications under real-world prehospital conditions, limited evidence is available regarding the stability of blood coagulation products stored in EMS vehicles.

Human fibrinogen concentrates and lyophilized human plasma (Octaplas LG AB) are increasingly available in prehospital emergency care for the early management of severe hemorrhage and trauma. Both products are subject to specific storage requirements defined by the manufacturer. Although these products are intended to be stored under controlled conditions, maintaining recommended storage environments continuously in operational EMS vehicles may be challenging, particularly during periods of elevated ambient temperatures. Data regarding the impact of such environmental exposure on product stability in the prehospital setting remain scarce.

The objective of this prospective observational longitudinal study is to evaluate the stability of fibrinogen concentrates and Octaplas LG AB when stored under routine operating conditions in a ground-based EMS ambulance in Graz, Austria. The study will be conducted during the summer months from July through September 2026, representing the period with the highest expected thermal stress on medical products stored in emergency vehicles.

At study initiation, reference samples of both products will be retained under manufacturer-recommended storage conditions. Additional study samples will be placed in the ambulance medication storage system and exposed to routine operational conditions throughout the observation period. Laboratory analyses will be performed at predefined monthly intervals to assess potential changes in product stability over time. All analyses will be conducted at the Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, using validated laboratory methods appropriate for each product. Product-specific stability parameters will be compared with baseline and reference samples stored according to manufacturer recommendations.

Environmental conditions will be continuously monitored throughout the study period. Temperature sensors will be installed both within the medication storage containers and inside the ambulance vehicle. Measurements will be recorded automatically at 10-minute intervals over the entire observation period. These data will be used to characterize environmental exposure profiles and to quantify the frequency, magnitude, and duration of deviations from recommended storage conditions.

The primary objective is to determine whether storage under real-world prehospital operating conditions results in measurable changes in the stability of fibrinogen concentrates and Octaplas LG AB over a three-month observation period. Secondary objectives are to characterize temperature conditions within EMS medication storage systems, assess compliance with manufacturer-recommended storage conditions, quantify environmental excursions outside recommended storage ranges, evaluate potential associations between environmental exposure and laboratory measures of product stability, and describe seasonal storage conditions encountered in a ground-based EMS system.

No patients will be enrolled, and no clinical interventions will be performed as part of this study. The investigation is limited to pharmaceutical product samples and environmental monitoring within an operational EMS vehicle. Consequently, no patient-related outcomes, safety endpoints, adverse events, or clinical efficacy outcomes will be assessed.

Descriptive statistics will be used to summarize environmental and laboratory data. Continuous variables will be reported as means with standard deviations or medians with interquartile ranges, as appropriate. Longitudinal changes in laboratory stability parameters will be assessed across repeated measurements obtained during the observation period. Associations between environmental variables, including temperature and laboratory indicators of product stability will be explored using correlation analyses and regression-based approaches where appropriate. Missing measurements, if encountered, will not be imputed and will be reported transparently.

The results of this study are expected to provide evidence regarding the suitability of current EMS storage practices for blood coagulation products under routine operating conditions. The findings may contribute to future recommendations for the storage, transport, and quality assurance of coagulation products used in prehospital emergency medicine.

Tipo de estudio

De observación

Inscripción (Estimado)

2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño
  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

N/A

Método de muestreo

Muestra no probabilística

Población de estudio

no study population

Descripción

Inclusion Criteria:

  • Fibryga samples stored in the participating ground-based EMS ambulance.
  • Octaplas LG AB samples stored in the participating ground-based EMS ambulance.
  • Samples available for laboratory analysis at the predefined study time points.
  • Samples exposed to routine operational storage conditions during the study period.

Exclusion Criteria:

  • Samples with damaged packaging.
  • Samples with incomplete storage documentation.
  • Samples accidentally removed from the designated storage system during the observation period.
  • Samples unavailable for laboratory analysis.
  • Samples exposed to conditions not representative of routine EMS operation.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Octaplas LG AB
Lyophilized human plasma samples stored under routine operating conditions in a ground-based EMS ambulance and analyzed longitudinally during the study period.
Fibrinogen conentrate
Human fibrinogen concentrate samples stored under routine operating conditions in a ground-based EMS ambulance and analyzed longitudinally during the study period.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Stability of fibrinogen concentrates and Octaplas LG AB During Storage Under Real-World EMS Conditions
Periodo de tiempo: Baseline to 3 months
Change in predefined laboratory stability parameters of fibrinogen concentrates and Octaplas LG AB after storage under routine operating conditions in a ground-based emergency medical service ambulance compared with baseline reference samples stored according to manufacturer recommendations.
Baseline to 3 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Frequency of Temperature Excursions Outside Recommended Storage Conditions
Periodo de tiempo: Continuously monitored from baseline to 3 months
Number and duration of temperature measurements exceeding manufacturer-recommended storage limits for Fibryga and Octaplas LG AB during the observation period.
Continuously monitored from baseline to 3 months
Maximum and Minimum Storage Temperatures
Periodo de tiempo: Baseline to 3 months
Highest and lowest temperatures recorded within medication storage compartments and inside the ambulance vehicle during the study period.
Baseline to 3 months
Compliance With Manufacturer-Recommended Storage Conditions
Periodo de tiempo: Continuously monitored from baseline to 3 months
Percentage of recorded measurements within the recommended storage conditions specified by the manufacturers of Fibryga and Octaplas LG AB.
Continuously monitored from baseline to 3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de julio de 2026

Finalización primaria (Estimado)

30 de septiembre de 2026

Finalización del estudio (Estimado)

30 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

9 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

9 de junio de 2026

Publicado por primera vez (Actual)

15 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de junio de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • MUG-STABLEEMS-2026-01

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir